SAN DIEGO and CAMBRIDGE, Mass. (PRWEB) March 28, 2018
CorTechs Labs, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce a distribution agreement with EnvoyAI, the leading artificial intelligence (AI) Exchange platform. NeuroQuant and its LesionQuant module, CorTechs Labs’ leading MR image post-processing solutions, which expand physicians’ resources for assessing and quantifying brain structure and lesion volumes, is now available for purchase on the EnvoyAI Exchange.
CorTechs Labs solutions provide valuable, automated, quantitative data on brain structures and lesions, aiding radiologists in providing supportive information to neurologists and other healthcare professionals. The solutions enhance clinical assessments, treatment planning, and disease progression monitoring of patients with neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, traumatic brain injury and more.
“We are entering an era of quantitative image analysis and EnvoyAI is excited to have CorTechs Labs’ FDA cleared quantitative imaging algorithms available through our Exchange,” said Dr. Steven Rothenberg, Chief Medical Officer at EnvoyAI. “Providing automated and objective measurements of brain structure volumes allows radiologists to provide more thorough assessments for patients and more complete reporting for referring physicians.”
“We are extremely pleased to partner with EnvoyAI and participate on their Exchange to provide access to quantitative imaging algorithms and data,” said Guri Stark, CEO of CorTechs Labs. “Over the last few years NeuroQuant has become the standard for brain volume measurements. EnvoyAI increases the reach and impact of these algorithms to enhance healthcare globally.”
CorTechs Labs’ flagship product, NeuroQuant, is the first FDA 510(k) cleared, CE marked, and Health Canada, Australia, and Korea licensed medical device software providing physicians with fast, accurate, proven and fully automated quantitative 3D T1 MRI post-processing image analysis. NeuroQuant is used by physicians worldwide in patients ranging from 3 to 100 years of age as a supplemental tool to measure brain structure volumes and confidently assess neurodegeneration of brain structures.
The LesionQuant module of NeuroQuant can assist physicians in their clinical evaluation process, clinical treatment planning and monitoring of disease progression by combining T2 FLAIR with 3D T1 scans for quantitative lesion analysis. It automatically visualizes lesions and lesion volume changes and provides longitudinal changes of brain structure volumes.
About CorTechs Labs
CorTechs Labs develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. CorTechs Labs’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma and brain development. CorTechs Labs is the intellectual property owner of the brain segmentation patents underlying FreeSurfer. Please visit http://www.cortechslabs.com for further information.
About EnvoyAI (http://www.envoyai.com) EnvoyAI facilitates the streamlined distribution and hospital implementation of trained machine learning algorithms via a vendor neutral distribution platform. EnvoyAI provides a developer platform, integrations, and an open API for algorithm developers, technology partners, and end users. EnvoyAI assists research institutions and emerging AI companies in the translation and commercialization processes, starting with rapid deployment via a scalable, secure, cloud-based infrastructure with the ability to add local components to facilitate on-site deployments as well. EnvoyAI also works with distribution partners to make algorithms on the platform available to a very wide footprint of hospitals and, ultimately, to physicians.